Αρχική World News Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses... World News Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis Από Ogkologos - 18 Ιουνίου, 2026 310 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Increasing Education About Cancer Screening and Prevention in Kazakhstan 11 Μαΐου, 2021 Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with... 26 Αυγούστου, 2022 COVID-19 Vaccine Myth Busters 28 Ιανουαρίου, 2021 ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... 21 Ιουλίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Opinion: ‘We can’t afford to stop now’ What Hodgkin Lymphoma Survivors Should Know About Mantle Radiation and Breast... Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian